FY2029 Earnings Forecast for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – HC Wainwright issued their FY2029 EPS estimates for shares of Monopar Therapeutics in a research report issued on Wednesday, January 22nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of $3.66 for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

Several other equities research analysts have also issued reports on MNPR. Piper Sandler initiated coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price for the company. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 price target on the stock.

Monopar Therapeutics Trading Up 16.8 %

Monopar Therapeutics stock opened at $39.32 on Thursday. The firm has a 50-day moving average price of $23.76 and a 200-day moving average price of $12.15. The firm has a market capitalization of $239.85 million, a PE ratio of -19.96 and a beta of 1.23. Monopar Therapeutics has a 12-month low of $1.54 and a 12-month high of $39.99.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09.

Insider Buying and Selling

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were acquired at an average price of $16.25 per share, with a total value of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 34.90% of the stock is currently owned by insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.